• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

晚期乳腺癌中的CDK4/6抑制剂，未来何去何从？

CDK4/6 inhibitors in advanced breast cancer, what is beyond?

作者信息

Mohammed Amrallah A, Rashied Hanaa, Elsayed Fifi Mostafa

机构信息

Medical Oncology Department, Faculty of Medicine, Zagazig University, Egypt.

King Salman Armed Forces Hospital, Tabuk City, KSA.

出版信息

Oncol Rev. 2019 Jul 29;13(2):416. doi: 10.4081/oncol.2019.416. eCollection 2019 Jul 22.

DOI:10.4081/oncol.2019.416
PMID:31452841
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6683209/
Abstract

Resistant to hormonal treatment considered the main clinical challenge in the management of advanced breast cancer (ABC). The use of CDK4/6 inhibitors (CDK4/6I) may change the treatment landscape. In this mandated review, we will focus on the applicable role of CDK4/6I in the management of HR+/HER2- ABC, mechanisms of resistance, and promising future implementation.

摘要

激素治疗耐药被认为是晚期乳腺癌（ABC）管理中的主要临床挑战。CDK4/6抑制剂（CDK4/6I）的使用可能会改变治疗格局。在这项授权综述中，我们将重点关注CDK4/6I在HR+/HER2-ABC管理中的适用作用、耐药机制以及未来有前景的应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fa7/6683209/1918299d3e33/onco-13-2-416-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fa7/6683209/31adde4f1668/onco-13-2-416-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fa7/6683209/c706b453ccd7/onco-13-2-416-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fa7/6683209/1918299d3e33/onco-13-2-416-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fa7/6683209/31adde4f1668/onco-13-2-416-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fa7/6683209/c706b453ccd7/onco-13-2-416-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fa7/6683209/1918299d3e33/onco-13-2-416-g003.jpg

相似文献

1
CDK4/6 inhibitors in advanced breast cancer, what is beyond?晚期乳腺癌中的CDK4/6抑制剂，未来何去何从？
Oncol Rev. 2019 Jul 29;13(2):416. doi: 10.4081/oncol.2019.416. eCollection 2019 Jul 22.
2
Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.Elacestrant（RAD1901）在多种对 CDK4/6 抑制剂耐药的 ER+ 乳腺癌模型中表现出抗肿瘤活性。
Breast Cancer Res. 2019 Dec 18;21(1):146. doi: 10.1186/s13058-019-1230-0.
3
CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update.用于治疗晚期激素受体阳性乳腺癌及其他疾病的CDK4/6抑制剂：2016年更新
Expert Opin Pharmacother. 2016 Aug;17(12):1657-67. doi: 10.1080/14656566.2016.1201072. Epub 2016 Jun 27.
4
Overcoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 Inhibitors.克服激素受体阳性晚期乳腺癌中的内分泌抵抗——CDK4/6抑制剂的新作用
Int J Cancer Clin Res. 2015;2(4). doi: 10.23937/2378-3419/2/4/1029. Epub 2015 Oct 14.
5
Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients.血浆衍生外泌体中 TK1 和 CDK9 的过表达与转移性乳腺癌患者对 CDK4/6 抑制剂的临床耐药相关。
Breast Cancer Res Treat. 2019 Nov;178(1):57-62. doi: 10.1007/s10549-019-05365-y. Epub 2019 Jul 26.
6
Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience.接受CDK4/6抑制剂治疗患者的Ki67和PR：一项真实世界经验
Diagnostics (Basel). 2020 Aug 8;10(8):573. doi: 10.3390/diagnostics10080573.
7
Targeting CDK4/6 pathways and beyond in breast cancer.乳腺癌中 CDK4/6 通路的靶向治疗及其他策略
Breast. 2019 Feb;43:8-17. doi: 10.1016/j.breast.2018.10.001. Epub 2018 Oct 8.
8
CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials.CDK4/6 抑制剂在晚期激素受体阳性/HER2 阴性乳腺癌中的应用：随机试验的系统评价和荟萃分析。
Breast Cancer Res Treat. 2018 Nov;172(1):9-21. doi: 10.1007/s10549-018-4901-0. Epub 2018 Jul 27.
9
Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response.乳腺癌中对CDK4/6抑制剂的耐药机制及反应的潜在生物标志物
Breast Care (Basel). 2017 Oct;12(5):304-308. doi: 10.1159/000484167. Epub 2017 Oct 27.
10
Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation.细胞周期蛋白依赖性激酶4和6抑制剂停用后乳腺癌疾病进展迅速
J Cancer. 2017 Jul 5;8(11):2004-2009. doi: 10.7150/jca.18196. eCollection 2017.

引用本文的文献

1
Thirteen-year analyses of medical oncology outpatient day clinic data: a changing field.十三年来医学肿瘤学门诊日诊数据的分析：一个不断变化的领域。
ESMO Open. 2020 Oct;5(5):e000880. doi: 10.1136/esmoopen-2020-000880.
2
Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor-Positive Breast Cancers.短期 CDK4/6 抑制使雌激素受体阳性乳腺癌放射增敏。
Clin Cancer Res. 2020 Dec 15;26(24):6568-6580. doi: 10.1158/1078-0432.CCR-20-2269. Epub 2020 Sep 23.

本文引用的文献

1
Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer.阿培利司治疗 - 突变型、激素受体阳性晚期乳腺癌。
N Engl J Med. 2019 May 16;380(20):1929-1940. doi: 10.1056/NEJMoa1813904.
2
Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.帕博西尼或瑞博西尼治疗晚期激素受体阳性、HER2 阴性乳腺癌的成本效果分析。
Breast Cancer Res Treat. 2019 Jun;175(3):775-779. doi: 10.1007/s10549-019-05190-3. Epub 2019 Mar 7.
3
CDK4/6 inhibition versus mTOR blockade as second-line strategy in postmenopausal patients with hormone receptor-positive advanced breast cancer: A network meta-analysis.
绝经后激素受体阳性晚期乳腺癌患者二线治疗策略中CDK4/6抑制剂与mTOR阻断剂的比较：一项网状Meta分析
Medicine (Baltimore). 2019 Jan;98(1):e13909. doi: 10.1097/MD.0000000000013909.
4
Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy.激素受体阳性晚期乳腺癌的预后特征及阿贝西利疗效的特征分析
NPJ Breast Cancer. 2018 Dec 18;4:41. doi: 10.1038/s41523-018-0094-2. eCollection 2018.
5
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.哌柏西利联合氟维司群治疗晚期乳腺癌的总生存期
N Engl J Med. 2018 Nov 15;379(20):1926-1936. doi: 10.1056/NEJMoa1810527. Epub 2018 Oct 20.
6
New and Important Changes in the TNM Staging System for Breast Cancer.乳腺癌TNM分期系统的新的重要变化。
Am Soc Clin Oncol Educ Book. 2018 May 23;38:457-467. doi: 10.1200/EDBK_201313.
7
The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial.帕博西尼联合氟维司群治疗乳腺癌耐药的遗传特征和克隆进化：PALOMA-3 临床试验研究。
Cancer Discov. 2018 Nov;8(11):1390-1403. doi: 10.1158/2159-8290.CD-18-0264. Epub 2018 Sep 11.
8
CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion.CDK4/6抑制剂在乳腺癌患者治疗中的应用：多学科圆桌讨论总结
ESMO Open. 2018 Aug 20;3(5):e000368. doi: 10.1136/esmoopen-2018-000368. eCollection 2018.
9
CDK4/6 inhibition in breast cancer: current practice and future directions.乳腺癌中的CDK4/6抑制：当前实践与未来方向
Ther Adv Med Oncol. 2018 Jul 17;10:1758835918786451. doi: 10.1177/1758835918786451. eCollection 2018.
10
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.MONALEESA-3：来曲唑和氟维司群治疗激素受体阳性、人表皮生长因子受体 2 阴性晚期乳腺癌的 III 期随机研究。
J Clin Oncol. 2018 Aug 20;36(24):2465-2472. doi: 10.1200/JCO.2018.78.9909. Epub 2018 Jun 3.